AbCellera Biologics (ABCL) Share-based Compensation (2020 - 2026)

AbCellera Biologics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $12.0 million for Q1 2026.

• Quarterly Share-based Compensation fell 18.75% year-over-year to $12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.0 million (down 18.38% YoY) and the FY2025 annual result came in at $55.8 million, down 17.44% from the prior year.
• Share-based Compensation was $12.0 million for Q1 2026 at AbCellera Biologics, down from $12.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $17.8 million in Q2 2024 and bottomed at $11.8 million in Q3 2022.
• A 5-year average of $14.6 million and a median of $14.8 million in 2025 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 126.48% — and 2025, when it dropped 20.1%.
• AbCellera Biologics' Share-based Compensation stood at $13.3 million in 2022, then grew by 23.46% to $16.4 million in 2023, then dropped by 7.43% to $15.2 million in 2024, then decreased by 15.25% to $12.9 million in 2025, then fell by 6.9% to $12.0 million in 2026.
• Business Quant data shows ABCL's Share-based Compensation at $12.0 million in Q1 2026, $12.9 million in Q4 2025, and $13.9 million in Q3 2025.